Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Stock Has Consensus Price Target of $10.00 According to Analysts

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) have been given an average rating of “Moderate Buy” by the seven brokerages that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $10.00.

AUTL has been the subject of several research analyst reports. Wall Street Zen raised Autolus Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, August 3rd. Finally, Weiss Ratings upgraded Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th.

Institutional Trading of Autolus Therapeutics

Large investors have recently modified their holdings of the business. Armistice Capital LLC boosted its position in shares of Autolus Therapeutics by 12.2% during the 4th quarter. Armistice Capital LLC now owns 17,500,000 shares of the company’s stock valued at $34,825,000 after acquiring an additional 1,900,000 shares during the last quarter. Syncona Portfolio Ltd purchased a new position in shares of Autolus Therapeutics during the second quarter worth about $26,625,152. Cetera Investment Advisers increased its position in shares of Autolus Therapeutics by 2.7% in the first quarter. Cetera Investment Advisers now owns 1,129,074 shares of the company’s stock worth $1,558,000 after purchasing an additional 29,324 shares during the last quarter. Alphabet Inc. bought a new position in shares of Autolus Therapeutics in the second quarter worth approximately $1,117,000. Finally, Hennion & Walsh Asset Management Inc. increased its position in shares of Autolus Therapeutics by 2.5% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 451,403 shares of the company’s stock worth $722,000 after purchasing an additional 11,197 shares during the last quarter. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Stock Up 4.3%

Shares of NASDAQ:AUTL opened at $1.69 on Thursday. The firm has a fifty day moving average price of $2.06 and a two-hundred day moving average price of $1.74. The company has a debt-to-equity ratio of 1.04, a current ratio of 4.89 and a quick ratio of 4.40. Autolus Therapeutics has a one year low of $1.18 and a one year high of $2.58. The company has a market cap of $449.82 million, a price-to-earnings ratio of -1.59 and a beta of 2.15.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.06. The firm had revenue of $45.69 million during the quarter, compared to analyst estimates of $38.56 million. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. Analysts anticipate that Autolus Therapeutics will post -0.75 EPS for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing programmed T-cell therapies for the treatment of cancer. The company’s platform is designed to genetically engineer T cells so they can recognize cancer targets, remain active in the body, and potentially reduce some limitations associated with conventional cell therapies.

Its lead product, obecabtagene autoleucel, is an autologous CAR T-cell therapy marketed in the United States as Aucatzyl.